KALV
$16.56
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs.
Recent News
VR Adviser Adds Over 1 Million Savara Shares
This clinical-stage biotech develops inhaled therapies for rare respiratory diseases, with its lead candidate in Phase III trials.
KalVista Pharmaceuticals Stock Sees RS Rating Jump To 86
The Relative Strength (RS) Rating for KalVista Pharmaceuticals stock entered a new percentile Wednesday, with a rise from 79 to 86. Decades of market research shows that the best-performing stocks typically have an 80 or higher RS Rating as they begin their biggest price moves. Is KalVista Pharmaceuticals Stock A Buy?
Wall Street Analysts Think KalVista Pharmaceuticals (KALV) Could Surge 117.1%: Read This Before Placing a Bet
The consensus price target hints at an 117.1% upside potential for KalVista Pharmaceuticals (KALV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
TD Cowen Bullish on KalVista Pharmaceuticals, Inc. (KALV) Ahead of Q4 Results
We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is placed twelfth on our list. TheFly reported on January 29 that TD Cowen analyst Stacy Ku raised its price target on KALV to $35 from $30 and maintained a Buy rating. The adjustment followed […]
Wall Street Analysts Believe KalVista Pharmaceuticals (KALV) Could Rally 116.4%: Here's is How to Trade
The consensus price target hints at an 116.4% upside potential for KalVista Pharmaceuticals (KALV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.